Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional
Last verified by NonDilute: 2026-06-08. Official notice and agency instructions control.
If you're building better predictive models for long-acting drug delivery, FDA/NIH will fund the computational and experimental work to replace expensive bridging studies.
Report stale or inaccurate summary
What this is
The U01 mechanism supports research teams in building predictive computational models that connect laboratory drug behavior to human pharmacokinetics for extended-release formulations—a critical gap in drug development. This is particularly relevant for pharmaceutical scientists, biotech researchers, and CROs developing long-acting injectables or implants who need regulatory-grade evidence of bioavailability without relying solely on expensive clinical studies. The optional clinical trial component allows well-positioned teams to validate models with real patient data, though the core funding focuses on mechanistic modeling and IVIVC framework development.
Who can apply
Eligibility details are unspecified in the source, but U01 grants typically support established research institutions (universities, non-profits, small businesses with R&D capacity). Solo founders without institutional affiliation or formal biotech infrastructure should verify eligibility via NIH grants.gov portal before investing application effort. Geographic eligibility likely includes U.S. entities only.
Topics: pbpk modeling · ivivc correlation · long-acting injectables · implantable drug products · pharmacokinetics · formulation development · regulatory science
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.